A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Risankizumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms IMMpact2
- Sponsors AbbVie
- 17 Dec 2018 Planned End Date changed from 27 Dec 2024 to 1 Nov 2024.
- 17 Dec 2018 Planned initiation date changed from 26 Feb 2019 to 22 Feb 2019.
- 21 Sep 2018 New trial record